Immune surveillance reactivation to improve overall survival in small cell lung cancer (SCLC): The randomized IMPULSE study
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based Toll-like receptor 9 (TLR...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 October 2016
|
| In: |
Annals of oncology
Year: 2016, Jahrgang: 27 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw389.10 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw389.10 Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/1432TiP/2800327 
|
| Verfasserangaben: | M. Thomas, R. Carter, S. Ponce Aix, J. Riera-Knorrenschild, A. Navarro Mendivil, M. Domine, J. Kollmeier, P. Sadjadian, R.M. Huber, M. Wolf |
| Zusammenfassung: | © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based Toll-like receptor 9 (TLR9) agonist, was compared to placebo in metastatic CRC (mCRC) patients with disease control after standard induction chemotherapy in the double-blind randomized phase 2 IMPACT study. Lefitolimod showed a superior effect over placebo in exploratory analyses of pretreatment characteristics that identified patients most likely to benefit from lefitolimod. A study in small cell lung cancer (SCLC) patients, IMPULSE, was designed to confirm this preliminary evidence of efficacy in a new, high-mortality-and-unmet-need indication.Trial design: Trial characteristics: IMPULSE is a randomized, international, multicenter, open-label trial to assess the effect of TLR9-mediated immune surveillance reactivation on overall survival (OS) in extensive-disease (ED) SCLC patients. Secondary endpoints include PFS, response rates, safety, and quality of... |
|---|---|
| Beschreibung: | Gesehen am 15.11.2017 |
| Beschreibung: | Online Resource |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw389.10 |